Thomas Knapp - Sucampo Pharmaceuticals President
President
Mr. Thomas J. Knapp is Executive Vice President, Chief Legal Officer and Corporationrationrate Secretary of Sucampo Pharmaceuticals, Inc., since March 2012. Mr. Knapp joined company in February 2010 as Senior Vice President, General Counsel and Corporationrationrate Secretary. Prior to joining the company, Mr. Knapp was of counsel at Exemplar Law Partners, LLC, and a partner and member at Knapp Law Firm beginning in 2008. From 2003 to 2008, he was Deputy General Counsel and then Vice President, General Counsel and Corporationrationrate Secretary at NorthWestern Corporationrationration, an electric and natural gas transmission and distribution company. Mr. Knapp served as of counsel at Paul Hastings LLP, a leading international law firm based in Washington, D.C., from 2001 to 2002. Previously in his career, Mr. Knapp was Assistant General Counsel at The Boeing Company from 1998 to 2000 and served as of counsel at Paul Hastings LLP, from 1996 to 1998. He held various inhouse positions, including as Labor Counsel, at The Burlington Northern Santa Fe Railway Company from 1980 to 1995 since 2012.
| Age | 62 |
| Tenure | 12 years |
| Phone | 301 961-3400 |
| Web | www.sucampo.com |
Sucampo Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0296 % which means that it generated a profit of $0.0296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 14.16 %, meaning that it created $14.16 on every $100 dollars invested by stockholders. Sucampo Pharmaceuticals' management efficiency ratios could be used to measure how well Sucampo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 293.54 M in liabilities with Debt to Equity (D/E) ratio of 740.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sucampo Pharmaceuticals has a current ratio of 5.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Sucampo Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Sucampo Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sucampo Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sucampo to invest in growth at high rates of return. When we think about Sucampo Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Barry Caldwell | Waste Management | 56 | |
| Jonathan Graham | Amgen Inc | 63 | |
| Michael Peterson | SEI Investments | 56 | |
| Todd Skulte | RadNet Inc | 55 | |
| Tara Hemmer | Waste Management | 51 | |
| Paul Klauder | SEI Investments | 50 | |
| Mital Patel | RadNet Inc | 38 | |
| Robert Crudup | SEI Investments | 69 | |
| Ryan Hicke | SEI Investments | 45 | |
| David Aardsma | Waste Management | 56 | |
| Puneet Bhasin | Waste Management | 52 | |
| Stuart Tross | Amgen Inc | 48 | |
| Darren Shade | Waste Management | 40 | |
| Scott Felenstein | National CineMedia | 55 | |
| Nikolaj Sjoqvist | Waste Management | 51 | |
| Lori Johnston | Amgen Inc | 53 | |
| Sean Harper | Amgen Inc | 54 | |
| Cynthia Patton | Amgen Inc | 56 | |
| Susan McGee | US Global Investors | 57 | |
| Derek Bomar | RadNet Inc | 46 | |
| Lawrence Snapp | National CineMedia | 78 | |
Management Performance
| Return On Equity | 14.16 | |||
| Return On Asset | 0.0296 |
Sucampo Pharmaceuticals Leadership Team
Elected by the shareholders, the Sucampo Pharmaceuticals' board of directors comprises two types of representatives: Sucampo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sucampo. The board's role is to monitor Sucampo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Sucampo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sucampo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Munder, Independent Director | ||
| Peter Pfreundschuh, CFO, Principal Financial Officer | ||
| Matthew Donley, Executive VP of HR | ||
| Max Donley, Executive Vice President of Human Resources | ||
| Peter Kiener, Chief Scientific Officer | ||
| Matthias Alder, Executive Vice President - Business Development & Licensing | ||
| Daniel Getman, Independent Chairman of the Board | ||
| Peter Greenleaf, Chairman and CEO | ||
| Silvia Taylor, Senior Vice President - Investor Relations, Public Relations and Corporate Communications | ||
| Peter Lichtlen, Chief Medical Officer | ||
| Stanley Miele, Sr. VP of Sales and Marketing and President of Sucampo Pharma Americas LLC | ||
| Andrew Smith, Principal Accounting Officer | ||
| Timothy Walbert, Director | ||
| John Johnson, Director | ||
| Paul Edick, Director | ||
| Alex Driggs, Acting General Counsel, Corporate Secretary | ||
| Karen Smith, Director | ||
| Robert Spiegel, Director | ||
| Maureen OConnell, Independent Director | ||
| Thomas Knapp, Executive Vice President Chief Legal Officer and Corporate Secretary |
Sucampo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sucampo Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 14.16 | |||
| Return On Asset | 0.0296 | |||
| Profit Margin | 7.80 % | |||
| Operating Margin | 30.77 % | |||
| Current Valuation | 1.05 B | |||
| Shares Outstanding | 47.09 M | |||
| Shares Owned By Insiders | 35.13 % | |||
| Shares Owned By Institutions | 82.48 % | |||
| Number Of Shares Shorted | 4.59 M | |||
| Price To Earning | (2.77) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sucampo Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sucampo Pharmaceuticals' short interest history, or implied volatility extrapolated from Sucampo Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Sucampo Stock
If you are still planning to invest in Sucampo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sucampo Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |